EyePoint Pharmaceuticals Bolsa (NASDAQ: EYPT)

EyePoint Pharmaceuticals (NASDAQ:EYPT) Bolsa

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals Inc

iRobot Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) &nbsp;announced the availability of a suite of new technologically-innovative Roomba&nbsp;vacuums and 2-in-1 vacuums and mops with advanced features, ranging from debris-compacting systems to extending and retractable dual-spinning mop pads that tackle stubborn messes.

News

Tech

IRBT

iRobot On Tuesday, Announced Suite of ROOMBA Floor Cleaning Robots

Guidance

VNET

VNET Expects 2025 Total Net Revenues Of RMB9.10B - RMB9.30B (Est RMB9.075B), Representing Growth Of 10% - 13% YoY

On June 7, 2022, Hello Group's board of directors authorized a share repurchase program under which the Company may repurchase up to US$200 million of its shares up to June 6, 2024 (the "Share Repurchase Program"). On March 14, 2024, Hello Group's board of directors approved to amend the Share Repurchase Program to (i) extend the term of the Share Repurchase Program up to June 30, 2026, and (ii) upsize the Share Repurchase Program to US$286.1 million. On March 12, 2025, Hello Group's board of directors approved an additional amendment to the Share Repurchase Program, to (i) extend the term of the Share Repurchase Program up to March 31, 2027, and (ii) upsize the Share Repurchase Program by another $200 million, so that the Company is authorized to, from time to time, acquire up to an aggregate of US$486.1 million worth of its shares in the form of ADSs and/or the ordinary shares of the Company in the open market and through privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. As of March 12, 2025, after the upsizing of the Share Repurchase Program, the remaining size of the program is US$222 million.

Buybacks

MOMO

Hello Gr Extends Share Buyback Program to March 31, 2027 (From Prior June 30, 2026), Upsizes Total Authorization By $200M to $486 Million

BingEx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>) reported quarterly earnings of $0.18 per share. The company reported $140.96 million in sales this quarter.

Earnings

BingEx Q4 EPADS $0.18, Sales $140.96M

VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.32 by 103.13 percent. The company reported quarterly sales of $307.80 million which missed the analyst consensus estimate of $2.08 billion by 85.17 percent. This is a 15.11 percent increase over sales of $267.39 million the same period last year.

Earnings Misses

VNET Q4 2024 GAAP EPADS $(0.01), Sales $307.75M

Exane BNP Paribas analyst Nate Crossett upgrades Medical Properties Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>) from Neutral to Outperform and raises the price target from $5 to $9.

Upgrades

Price Target

Analyst Ratings

Exane BNP Paribas Upgrades Medical Properties Trust to Outperform, Raises Price Target to $9

Hello Group's board of directors has declared a special cash dividend in the amount of US$0.30 per ADS, or US$0.15 per ordinary share. The cash dividend will be paid on April 30, 2025 to shareholders of record at the close of business on April 11, 2025. The ex-dividend date will be April 11, 2025. The aggregate amount of cash dividends to be paid is approximately US$50 million, which will be funded by available cash on the Company's balance sheet.

Dividends

Hello Gr Board Declared A Special Cash Dividend Of $0.30/ADS

B. Riley Securities analyst Yuan Zhi initiates coverage on Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) with a Buy rating and announces Price Target of $15.

Initiation

RADX

B. Riley Securities Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $15

Deutsche Bank analyst Brian Bedell maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Buy and lowers the price target from $75 to $61.

HOOD

Deutsche Bank Maintains Buy on Robinhood Markets, Lowers Price Target to $61

BMO Capital analyst Kostas Biliouris initiates coverage on Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Outperform rating and announces Price Target of $72.

BMO Capital Initiates Coverage On Avidity Biosciences with Outperform Rating, Announces Price Target of $72

Fortuna Mining Provided Its Updated Mineral Reserve And Mineral Resource Estimates As Of December 31, 2024, For Its Four Operating Mines In West Africa And The Americas As Well As The Arizaro Project Located At The Lindero Mine In Salta, Argentina, The Diamba Sud Gold Project In Senegal And The San Jose Mine In Mexico

The odds of a US recession occurring in 2025 have escalated due to the imposition of tariffs, as per&nbsp;Alec Kersman, managing director and&nbsp;head of Asia-Pacific at Pimco.
What Happened: Alec Kersman, speaking at <a href="https://www.cnbc.com/2025/03/12/tariffs-have-increased-the-probability-of-a-us-recession-pimco.html">CNBC&#8217;s</a> CONVERGE event in Singapore on Wednesday, revealed that there is now a 35% chance of a US recession this year. This figure marks a considerable surge from the 15% probability Pimco projected in December 2024, primarily due to the impact of tariffs enforced by the US.
However, Kersman also pointed out that Pimco&#8217;s base case scenario is a growth of 1% to 1.5% in the U.S. economy, a significant drop from previous forecasts, but still an expansion.
On the other hand, Kamal Bhatia, president and CEO&nbsp;of Principal Asset Management, told CNBC that trade policies leading to increased domestic consumption could potentially boost the U.S. economy more than anticipated. Bhatia noted that trade wars could prompt countries to become more insular, fostering patriotism that translates into increased local spending.
Consumer spending, which constitutes approximately two-thirds of U.S. gross domestic product, could rise due to tariffs, potentially causing the country&#8217;s GDP to perform better than expected, Bhatia added.
SEE ALSO: <a href="https://www.benzinga.com/markets/equities/25/03/44269513/elon-musk-says-tesla-will-double-us-production-in-2-years-after-trump-backs-ev-giant-amid-stock-slump">Elon Musk Says Tesla Will Double US Production in 2 Years After Trump Backs EV Giant Amid Stock Slump</a>
Why It Matters: The 25% tariffs on steel and aluminum imports imposed by U.S. President Donald Trump have now taken effect, triggering a <a href="https://www.benzinga.com/markets/equities/25/03/44269301/trumps-25-tariffs-on-steel-and-aluminum-imports-take-effect-eu-retaliates-us-steel-nucor-century-aluminum-and-other-domestic-stocks-cheer">swift retaliation</a> from the European Union. This move has impacted several countries, including Canada, Australia, and the EU. "We've had very muted geopolitics in investing for a long period of time, and clearly tariffs are changing that," opined Bhatia.
While the tariffs have fueled a buying frenzy and sent Hot Rolled Coil (HRC) prices soaring 36% year-to-date, real demand hasn&#8217;t budged, according to JPMorgan analyst Bill Peterson. The <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44245031/steels-hot-streak-faces-reality-check-analyst-weighs-tariffs-vs-recession-fears">looming economic uncertainty</a>, coupled with demand stagnation and rising scrap costs, could prevent stocks from fully cashing in.
<ul>
<li>READ MORE:<a href="https://www.benzinga.com/25/03/44267277/trump-scraps-50-tariff-hike-on-canadian-steel-aluminum-after-ontario-backs-down"> Trump Scraps 50% Tariff Hike On Canadian Steel, Aluminum After Lutnick Talks With Ontario Premier</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

US Recession Risk Surges To 35%, Pimco Cautions On Economic Fallout From Trump's Tariffs

BMO Capital analyst Kostas Biliouris initiates coverage on Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Outperform rating and announces Price Target of $50.

BMO Capital Initiates Coverage On Dyne Therapeutics with Outperform Rating, Announces Price Target of $50

BMO Capital analyst Kostas Biliouris initiates coverage on Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Outperform rating and announces Price Target of $50.

RCKT

BMO Capital Initiates Coverage On Rocket Pharmaceuticals with Outperform Rating, Announces Price Target of $50

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is adding some heavy metal firepower to its Vision Pro headset — but will a virtual concert featuring Metallica be enough to spark new interest in the struggling $3,499 device?
What Happened: On Friday, March 14, Apple Vision Pro users will be able to experience Metallica: M72 World Tour &#8211; Live from Mexico City — a 25-minute immersive concert filmed with 14 ultra-high-resolution 180-degree cameras and powered by Spatial Audio.
The experience offers unprecedented access to the band's finale performance and will also be available as an EP on Apple Music.
See Also: <a href="https://in.benzinga.com/25/03/44267530/while-apple-reportedly-mulls-over-ar-glasses-google-bets-big-on-eye-tracking-tech-with-115-million-adhawk-acquisition-report">Apple&#8217;s AR Glasses Approach Aside, Google Makes Its Move On Eye-Tracking Tech With $115 Million AdHawk Acquisition: Report</a>
In addition to streaming at home, the concert will serve as a demo experience at Apple Stores where Vision Pro is available, including in the U.S., Canada, U.K., Germany, and more.
Why It's Important: This comes as Apple appears to be reevaluating its extended reality (XR) strategy. Last year, it was reported that the tech giant has <a href="https://www.benzinga.com/general/gaming/24/10/41499682/apple-to-cut-vision-pro-production-cheaper-model-expected-in-2025-report">scaled back Vision Pro production</a> due to lower-than-expected demand. CEO Tim Cook has also admitted the headset isn't a mass-market product at its current price.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
In the latest installment of his weekly "Power On" newsletter, Bloomberg columnist Mark Gurman reported that <a href="https://in.benzinga.com/tech/25/03/44211544/apple-breaks-tradition-with-a-flood-of-new-releases-explores-smart-glasses">Apple is exploring various form</a> factors.
After scrapping its plans for AR glasses as an external Mac display in early 2025, the company is once again considering standalone AR glasses.
According to the report, a commercial version could take anywhere from three to five years to materialize. Apple is also reportedly developing its take on Meta's Ray-Ban smart glasses. 
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/03/44207932/apple-delays-next-gen-siri-its-going-to-take-us-longer-than-we-thought-to-deliver-ai-upgrades" target="_blank" rel="noreferrer noopener">Apple Delays Next-Gen Siri: ‘It&#8217;s Going To Take Us Longer Than We Thought&#8217; To Deliver AI Upgrades</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

AAPL

Apple Doubles Down On Vision Pro With Metallica Concert Experience: But Can Rock Legends Save A $3,499 Headset That's Already Being Scaled Back?

The United States has lifted its pause on intelligence sharing and resumed security assistance to Ukraine following Ukraine&#8217;s acceptance of a U.S.-proposed 30-day ceasefire plan, according to a joint statement released Tuesday. However, an influential Russian lawmaker quickly rejected American terms, and <a href="https://in.benzinga.com/25/03/44138112/defense-stocks-take-centerstage-as-donald-trump-freezes-ukraine-military-aid-heres-a-list-of-top-global-defense-etfs-to-watch">defense stocks fell in response</a>.
What Happened: The agreement came during a meeting in Jeddah, Saudi Arabia, where Ukrainian representatives expressed &#8220;readiness to accept the U.S. proposal to enact an immediate, interim 30-day ceasefire,&#8221; which could be extended by mutual agreement and requires Russian acceptance and implementation.
Markets reacted swiftly to the news. The Nasdaq 100, tracked by Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), reversed earlier losses and surged more than 400 points from its intraday low, closing up 0.7% on Tuesday. 
Meanwhile, major defense contractors saw their shares decline. L3Harris Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) fell 2.53%, Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) dropped 2.15%, and General Dynamics Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) declined 2.88% as investors recalibrated expectations <a href="https://in.benzinga.com/25/03/44138112/defense-stocks-take-centerstage-as-donald-trump-freezes-ukraine-military-aid-heres-a-list-of-top-global-defense-etfs-to-watch">amid peace prospects</a>.
Konstantin Kosachev, chairman of the international affairs committee of Russia&#8217;s Federation Council, pushed back against the proposal Wednesday, stating on Telegram that any agreement would be &#8220;on our terms, not on American,&#8221; reported Reuters. Kosachev added, &#8220;This is not boasting, but understanding that real agreements are still being written there, at the front.&#8221;
See Also: <a href="https://www.benzinga.com/25/03/44267113/ark-invests-strategic-moves-tempus-ai-block-inc-and-draftkings-inc-in-focus">Cathie Wood&#8217;s Ark Invest Continues To Load Up On Tempus AI, Dumps Bitcoin-Focused Block In Tech Meltdown Aftermath</a>
Why It Matters: The ceasefire development follows President Donald Trump&#8216;s recent threat to impose &#8220;large-scale banking sanctions, sanctions, and tariffs on Russia&#8221; until a peace agreement is reached. Earlier this month, Trump had paused military aid to Ukraine, pressuring President Volodymyr Zelensky to pursue peace with Russia following a contentious Oval Office meeting.
Prediction markets have shown increasing confidence in a resolution, with Polymarket data indicating a 37% probability of Trump brokering a ceasefire within his first 90 days in office, up from 23% <a href="https://www.benzinga.com/25/03/44260839/tech-stocks-bitcoin-strongly-rebound-as-ukraine-backs-us-proposal-for-30-day-ceasefire-with-russia">before the announcement</a>. 
As part of the agreement, both countries also committed to concluding &#8220;a comprehensive agreement for developing Ukraine&#8217;s critical mineral resources&#8221; that would expand Ukraine&#8217;s economy and secure its long-term prosperity.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44263206/warren-buffett-rakes-in-607-million-while-elon-musk-jeff-bezos-and-other-top-moneybags-bleed-67-bill" target="_blank" rel="noreferrer noopener">Warren Buffett Rakes In $607 Million While Elon Musk, Jeff Bezos, And Other Top Moneybags Bleed $67 Billion In A Day Amid Market Wipeout</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Global

Economics

Trump Restores Ukraine Aid After Threatening 'Large-Scale' Sanctions On Moscow, But Russian Lawmaker Rejects Ceasefire Terms: Defense Stocks Fall

<h3>Companies Reporting Before The Bell</h3>
• EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) is projected to report quarterly loss at $0.07 per share on revenue of $23.36 million. 
• Hello Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $365.05 million. 
• Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) is estimated to report quarterly earnings at $0.56 per share on revenue of $14.19 million. 
• Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) is expected to report earnings for its fourth quarter. 
• Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $67.84 million. 
• VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $284.88 million. 
• Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) is likely to report quarterly earnings at $0.06 per share on revenue of $107.94 million. 
• Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $200.59 million. 
• Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $1.15 billion. 
• Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $194.15 million. 
• OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $30.36 million. 
• Navigator Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVGS#NYSE">NVGS</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $120.87 million. 
• ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) is projected to report quarterly earnings at $0.78 per share on revenue of $2.09 billion. 
• Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $265.85 million. 
• Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) is expected to report quarterly loss at $0.03 per share on revenue of $32.37 million. 
• ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) is expected to report quarterly earnings at $3.49 per share on revenue of $2.02 billion. 
• Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $161.60 million. 
• National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $339.84 million. 
• iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) is expected to report quarterly loss at $1.73 per share on revenue of $171.00 million. 
• Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) is expected to report quarterly loss at $0.09 per share on revenue of $5.75 million. 
• BingEx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>) is expected to report earnings for its fourth quarter. 
• InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is likely to report quarterly loss at $0.19 per share on revenue of $1.82 million. 
• United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) is estimated to report earnings for its fourth quarter. 
• Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $24.15 million. 
• MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) is expected to report quarterly loss at $0.19 per share on revenue of $61.57 million. 
<h3>Companies Reporting After The Bell</h3>
• Vasta Platform (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTA#NASDAQ">VSTA</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $110.28 million. 
• KLX Energy Services Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) is expected to report quarterly loss at $0.80 per share on revenue of $168.90 million. 
• Algoma Steel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) is expected to report earnings for its third quarter. 
• Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) is projected to report quarterly loss at $0.25 per share on revenue of $129.53 million. 
• Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) is estimated to report earnings for its fourth quarter. 
• Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $44.59 million. 
• Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) is expected to report quarterly loss at $0.19 per share on revenue of $36.66 million. 
• Montauk Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTK#NASDAQ">MNTK</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $56.32 million. 
• Ellington Credit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $9.65 million. 
• FreightCar America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $152.02 million. 
• PHX Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $8.93 million. 
• Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) is expected to report quarterly earnings at $1.82 per share on revenue of $1.64 billion. 
• SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) is estimated to report quarterly loss at $0.21 per share on revenue of $222.33 million. 
• ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) is likely to report earnings for its fourth quarter. 
• UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $425.34 million. 
• SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) is estimated to report quarterly loss at $1.50 per share on revenue of $710 thousand. 
• RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) is expected to report quarterly earnings at $0.83 per share on revenue of $79.00 million. 
• Beauty Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) is projected to report quarterly loss at $0.09 per share on revenue of $77.45 million. 
• Fathom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHM#NASDAQ">FTHM</a>) is projected to report quarterly loss at $0.17 per share on revenue of $84.70 million. 
• Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $63.63 million. 
• Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $51.20 million. 
• Limoneira (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) is projected to report quarterly loss at $0.17 per share on revenue of $40.70 million. 
• Calavo Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) is expected to report quarterly earnings at $0.29 per share on revenue of $161.55 million. 
• KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) is likely to report quarterly loss at $0.02 per share on revenue of $8.89 million. 
• American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) is likely to report quarterly earnings at $0.51 per share on revenue of $1.60 billion. 
• Berry Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $173.00 million. 
• Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) is projected to report quarterly loss at $0.19 per share on revenue of $108.91 million. 
• Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) is projected to report quarterly earnings at $4.97 per share on revenue of $5.66 billion. 
• electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) is expected to report quarterly loss at $0.34 per share on revenue of $7.29 million. 
• AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $9.73 million. 
• BGSF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $67.65 million. 
• CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) is projected to report earnings for its fourth quarter. 
• Companhia Siderurgica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SID#NYSE">SID</a>) is projected to report quarterly loss at $0.09 per share on revenue of $1.94 billion. 
• Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $34.15 million. 
• Urgently (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) is expected to report earnings for its fourth quarter. 
• Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $28.67 million. 
• Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $73.63 million. 
• CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) is estimated to report earnings for its fourth quarter. 
• Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) is expected to report earnings for its third quarter. 
• Zedge (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZDGE#AMEX">ZDGE</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $7.71 million. 
• NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) is expected to report quarterly loss at $0.14 per share on revenue of $1.73 million. 
• Monogram Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) is estimated to report earnings for its fourth quarter. 
• Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) is likely to report earnings for its fourth quarter. 
• Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $29.00 million. 
• Aris Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMN#AMEX">ARMN</a>) is likely to report earnings for its fourth quarter. 
• Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $116.82 million. 
• Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) is expected to report quarterly loss at $0.29 per share on revenue of $159.90 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADBE

AEYE

AMRN

ANIK

ARCO

ARIS

ARMN

ASRT

ASTL

BGSF

BRLT

BTMD

CDLX

CINT

CMTL

CPSH

CVGW

EARN

ECOR

FOSL

FTHM

HBIO

KEQU

KLXE

KRMD

LEGH

LMNR

LOGC

MGRM

MNTK

NESR

NKTR

NSPR

NVGS

ONDS

OPRX

PATH

PHLT

QRHC

RAIL

RCMT

REFI

SDHC

SEAT

SKIN

SNES

TLYS

UPLD

VSTA

ZDGE

Earnings Scheduled For March 12, 2025

Billionaire investor Howard Marks has highlighted the shifting investor sentiment toward credit investments amid the ongoing downfall in the equity markets. In his latest memo, he underscores how private debt offers higher returns than the S&amp;P 500 index amid elevated valuations.
What Happened: In his latest memo &#8216;Gimme Credit,&#8217; dated March 6, Marks explains how credit investments, especially private credit, is an attractive asset class with higher return potential, but he cautions investors to be aware of its unique risks, particularly the lack of transparency and the uncertainty surrounding its performance in a future crisis.
Despite the current narrow spreads of around 290 basis points, the co-founder and co-chairman of Oaktree Capital Management argues that credit investments offer healthy absolute returns and are fairly priced in relative terms.
&#8220;The current level of offered yields implies higher returns from credit than the S&amp;P 500, with returns that are contractual and thus subject to much less variability and uncertainty,&#8221; the memo states.
Comparing his latest analysis to his Jan. 7 memo, &#8216;<a href="https://www.benzinga.com/markets/equities/25/01/42995814/billionaire-investor-who-predicted-the-dot-com-crash-25-years-ago-warns-of-another-market-storm-brewing-in-the-us">On Bubble Watch</a>,&#8217; he describes that at current valuations the S&amp;P 500 index is likely to produce ten-year returns averaging between -2% and 2% per year. However, this is not the case with today's expected returns on credit.
&#8220;We'd rather buy at higher yields and wider spreads, and we may get a chance to do so . . . or not. But that preference in itself isn't a reason for not increasing allocations to credit today,&#8221; he writes.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/03/44245897/billionaire-investor-ron-baron-reacts-to-nasdaq-sp-selloff-the-stock-prices-cant-believe-how-cheap-they-are">Billionaire Investor Ron Baron Reacts To Nasdaq, S&amp;P Selloff: &#8216;The Stock Prices&#8230;Can&#8217;t Believe How Cheap They Are&#8217;</a>
Why It Matters: Contrasting the difference between buying the S&amp;P 500 at current valuations versus buying private credit at lower spreads, the dot-com crash predictor explains that high-yield bond investors earned more than Treasuries in 10 years.
According to him, the reason for this is that &#8220;The issuer pays interest and principal as promised, the price decline brought on by spread widening has only a temporary effect. When you're repaid at par, you'll have received the yield you expected, regardless of price fluctuations experienced in the meantime, including declines related to spread widening.&#8221;
Also, investing at lower yields is not a major issue as per Marks because of the following reasons;
<ul>
<li>Historical spreads cover default losses.</li>
<li>Improved economic management has reduced default risk.</li>
<li>Total return, not just spread, is the key metric.</li>
<li>Consistent interest payments and principal repayment prevail.</li>
<li>Contractual bond returns provide stability.</li>
<li>Active management further reduces default risk.</li>
</ul>
However, some cons of investing in private credit include;
<ul>
<li>Illiquidity: Funds locked, no quick exits.</li>
<li>Unproven In Crisis: Untested during severe downturns.</li>
<li>Potential For Lax Standards: Risk of rushed, poor-quality loans.</li>
<li>Marking To Model Risk: Valuation subjectivity, potential for overvaluation.</li>
<li>Lack Of Transparency: Limited public information and regulation.</li>
<li>Higher Fees: Increased costs compared to public credit.</li>
</ul>
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell on Tuesday. The SPY was down 0.83% to $555.92, and the QQQ also declined 0.24% to $471.60, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44268732/uber-axes-foodpanda-takeover-deal-in-taiwan-heres-what-benzingas-edge-rankings-show">Uber Axes Foodpanda Takeover Deal In Taiwan: Here&#8217;s What Benzinga&#8217;s Edge Rankings Show</a></li>
</ul>
Photo courtesy: Oaktreecapital

Market Summary

Bonds

Billionaire Howard Marks Prefers Credit Over Equity Amid Falling Market: 'Yields Implies Higher Returns From Credit Than The S&P 500'

In a bid to regain his $56 billion compensation, Elon Musk filed an appeal challenging a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42279851/elon-musk-56b-pay-package-rejected-by-judge-again-tesla-analyst-says-a-soap-opera-playing-out-in-delaware">lower court&#8217;s decision to overturn</a> the record payout from Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>). Musk on Tuesday contended that the judge committed several legal errors in the ruling.
What Happened: <a href="https://www.benzinga.com/24/12/42495275/elon-musk-can-now-appeal-to-restore-56-billion-pay-package-from-tesla-report">Musk&#8217;s appeal </a>asserts that his 2018 pay package, which shareholders approved twice, significantly contributed to Tesla&#8217;s growth. However, the Court of Chancery deemed it unfair to shareholders, Reuters reported.
The appeal brief, submitted by Musk along with the current and former Tesla directors listed as defendants in the case, contends that the court&#8217;s ruling &#8220;defies settled principles of Delaware law, sound corporate governance, and common sense.&#8221;
Tesla did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment. 
In January 2024, Chancellor Kathaleen McCormick revoked <a href="https://www.benzinga.com/tech/25/01/42893922/tesla-directors-receives-court-approval-for-settlement-in-excess-pay-case">Musk&#8217;s stock options pay package</a>, calling it &#8220;unfathomable.&#8221; She contended that the decision was unfair to Tesla shareholders, as the directors who approved it were influenced by Musk, and Tesla failed to disclose essential information to investors before they cast their votes.
Musk&#8217;s compensation package granted him the option to purchase approximately 303 million Tesla shares at about $23 each, provided the company met specific performance and valuation targets.
SEE ALSO: <a href="https://www.benzinga.com/markets/equities/25/03/44239714/teslas-101x-valuation-raises-alarm-as-gordon-johnson-warns-of-sales-slump-dan-ives-sees-ai-upside-despite-elon-musks-doge-distractions">Tesla&#8217;s 101x Valuation Raises Alarm As Gordon Johnson Warns Of Sales Slump, Dan Ives Sees AI Upside Despite Elon Musk&#8217;s DOGE Distractions</a>
Why It Matters: This appeal comes after Musk&#8217;s vocal criticism of Delaware&#8217;s legal system. Following the rejection of his nearly $100 billion compensation package from Tesla, Musk did not hold back in expressing his dissatisfaction with the state&#8217;s Court of Chancery, <a href="https://www.benzinga.com/news/25/02/44031641/elon-musk-blasts-delaware-court-after-100b-pay-package-rejected-sparks-corporate-exodus-threat">which he described</a> as &#8220;absolute corrupt&#8221;. The appeal is essential for reinstating Musk&#8217;s compensation and ensuring his continued commitment to Tesla. Musk has suggested that he desires a larger stake in the company; otherwise, he may pursue product development outside of Tesla.
Notably, Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), TripAdvisor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>), and Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) are also considering moving out of Delaware to re-incorporate in places like Nevada and Florida. As a result, the state is looking to revise its policies for handling shareholder lawsuits.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/equities/25/03/44268904/elon-musks-current-leadership-situation-is-not-sustainable-for-shareholders-says-tesla-bull-needs-to-strike-a-balance-with-doge">Elon Musk&#8217;s &#8216;Current Leadership Situation Is Not Sustainable For&#8230;Shareholders,&#8217; Says Tesla Bull: &#8216;Needs To Strike A Balance With DOGE&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

TRIP

TSLA

Elon Musk Challenges Judge's Decision, Seeks Reinstatement Of Record $56 Billion Tesla Payout

For the first quarter of 2025, the Company expects total net revenues to be between RMB2.4 billion to RMB2.5 billion, representing a decrease of 6.3% to 2.4% year over year. This forecast reflects the Company's current and preliminary views on the market and operational conditions, which are subject to change.

Hello Gr Expects Q1 Revenue Of RMB2.4B-RMB2.5B, Down 6.3% To 2.4% YoY

Management

Press Releases

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

EyePoint Provides Company Update and Anticipated Development Milestones for 2025

Health Care

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

EyePoint Announces Participation at Upcoming Investor Conferences

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

Comments

EyePoint Pharmaceuticals

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL